patent expiration

Efforts to Protect Lipitor from Generic Competition: Cause for Concern?

Posted on 06/20/2013 by |AARP Blog Author | Comments

Public Policy InstituteA new Rx Price Watch report examines the strategies reportedly used by Pfizer to try to maintain revenue and market share for its popular anti-cholesterol drug Lipitor as its patent expired. Pfizer’s tactics raise important concerns for consumers and publicly funded programs like Medicare. The patent for Lipitor was originally expected to expire no later than June 2011 after 14 years on the market. In response, Pfizer reportedly developed an unprecedented strategy to protect and extend Lipitor sales, which included: …

State Laws Could Hamper Savings from Biosimilar Drugs

Posted on 05/30/2013 by |AARP Blog Author | Comments

Public Policy Institute  Many consumers have benefited from the recent increase in brand-name drugs that are going off patent, allowing less expensive generic drugs to enter the market.  The same may happen with a new type of drugs known as biologics — but only if the generic versions of these drugs are allowed to reach consumers. Biologic drugs are medicines derived from living organisms that are often used to treat health conditions that commonly affect older populations, such as cancer, multiple sclerosis …